STAT3 and small cell lung carcinoma: Studies have shown that in the microenvironment of interleukin (IL)-23-mediated tumor inflammation, the STAT3/VEGF pathway activates to induce resistance to doxorubicin in small-cell lung cancer (SCLC) cells [59].